Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA99055
Max Phase: Preclinical
Molecular Formula: C23H22F6N4O2
Molecular Weight: 500.44
Molecule Type: Small molecule
Associated Items:
ID: ALA99055
Max Phase: Preclinical
Molecular Formula: C23H22F6N4O2
Molecular Weight: 500.44
Molecule Type: Small molecule
Associated Items:
Synonyms (1): L-741671
Synonyms from Alternative Forms(1):
Canonical SMILES: O=c1[nH]nc(CN2CCC[C@H](OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H]2c2ccccc2)[nH]1
Standard InChI: InChI=1S/C23H22F6N4O2/c24-22(25,26)16-9-14(10-17(11-16)23(27,28)29)13-35-18-7-4-8-33(12-19-30-21(34)32-31-19)20(18)15-5-2-1-3-6-15/h1-3,5-6,9-11,18,20H,4,7-8,12-13H2,(H2,30,31,32,34)/t18-,20-/m0/s1
Standard InChI Key: ZUWHBRRBKKTMQO-ICSRJNTNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 500.44 | Molecular Weight (Monoisotopic): 500.1647 | AlogP: 5.06 | #Rotatable Bonds: 6 |
Polar Surface Area: 74.01 | Molecular Species: ACID | HBA: 4 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 5.87 | CX Basic pKa: 7.03 | CX LogP: 4.21 | CX LogD: 4.14 |
Aromatic Rings: 3 | Heavy Atoms: 35 | QED Weighted: 0.46 | Np Likeness Score: -0.81 |
1. Ladduwahetty T, Baker R, Cascieri MA, Chambers MS, Haworth K, Keown LE, MacIntyre DE, Metzger JM, Owen S, Rycroft W, Sadowski S, Seward EM, Shepheard SL, Swain CJ, Tattersall FD, Watt AP, Williamson DW, Hargreaves RJ.. (1996) N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists., 39 (15): [PMID:8709125] [10.1021/jm9506534] |
2. Takeuchi Y, Shands EF, Beusen DD, Marshall GR.. (1998) Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor., 41 (19): [PMID:9733486] [10.1021/jm9700171] |
3. Evers A, Klebe G.. (2004) Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model., 47 (22): [PMID:15481976] [10.1021/jm0311487] |
4. Wu YJ, Meanwell NA.. (2021) Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design., 64 (14.0): [PMID:34213340] [10.1021/acs.jmedchem.1c00790] |
Source(1):